Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):421-424.e2. doi: 10.1016/j.clml.2021.01.010. Epub 2021 Jan 20.

Affiliations

¹ Department of Medicine, University of South Florida, Tampa, FL.
² Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
³ Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT.
⁴ Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL.
⁵ Department of Hematology and Oncology, H. Lee Moffitt Cancer Center, Tampa, FL. Electronic address: David.Sallman@moffitt.org.

PMID: 33583730
DOI: 10.1016/j.clml.2021.01.010

No abstract available

Keywords: AML; Acute myeloid leukemia; Immunotherapy; MDS; Myelodysplastic syndrome.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Combined Modality Therapy
Disease Management
Disease Susceptibility
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Drug-Related Side Effects and Adverse Reactions / etiology*
Humans
Immune Checkpoint Inhibitors / adverse effects*
Immune Checkpoint Inhibitors / therapeutic use
Leukemia, Myeloid / complications*
Leukemia, Myeloid / diagnosis
Leukemia, Myeloid / drug therapy
Leukemia, Myeloid / etiology
Molecular Targeted Therapy / adverse effects*
Molecular Targeted Therapy / methods
Myeloproliferative Disorders / complications*
Myeloproliferative Disorders / diagnosis
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / etiology
Prognosis
Retreatment
Treatment Failure
Treatment Outcome

Substances

Biomarkers
Immune Checkpoint Inhibitors